Scarica l'app Stockscreener
6.87
1.71%
0.1157
Dopo l'orario di chiusura:
6.94
0.07
+1.02%
Precedente Chiudi:
$6.7543
Aprire:
$6.75
Volume 24 ore:
17,664
Relative Volume:
0.13
Capitalizzazione di mercato:
$3.77M
Reddito:
$49,300
Utile/perdita netta:
$-6.27M
Rapporto P/E:
-0.7558
EPS:
-9.09
Flusso di cassa netto:
$-5.38M
1 W Prestazione:
+6.02%
1M Prestazione:
-7.16%
6M Prestazione:
+55.15%
1 anno Prestazione:
-17.39%
Intervallo 1D:
$6.52
$7.00
Intervallo di 1 settimana:
$6.30
$7.00
Portata 52W:
$0.7425
$562.68
Aclarion Inc Stock (ACON) Company Profile
Nome
Aclarion Inc
Settore
Industria
Telefono
833 275 2266
Indirizzo
8181 ARISTA PLACE, BROOMFIELD
Confronta ACON con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACON
Aclarion Inc
|
6.87 | 3.77M | 49,300 | -6.27M | -5.38M | -9.09 |
|
VEEV
Veeva Systems Inc
|
285.36 | 45.71B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
62.07 | 9.42B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
58.85 | 9.78B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
111.55 | 8.70B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
41.16 | 6.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
Aclarion Inc Borsa (ACON) Ultime notizie
Aclarion (NASDAQ:ACON) Upgraded by Wall Street Zen to Hold Rating - Defense World
Aclarion stock price target cut to $20 at Ascendiant Capital - Investing.com Australia
Aclarion stock price target cut to $20 at Ascendiant Capital By Investing.com - Investing.com India
Aclarion, Inc. (NASDAQ:ACON) Sees Large Drop in Short Interest - Defense World
Aclarion (NASDAQ:ACON) Trading Down 1.2% – Here’s Why - Defense World
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site - Ortho Spine News
USC Medical Center Joins Groundbreaking AI Trial to Revolutionize Chronic Back Pain Diagnosis - Stock Titan
Aclarion, Inc. SEC 10-Q Report - TradingView
Aclarion (ACON) Expands CLARITY Trial with Texas Back Institute - GuruFocus
Aclarion Announces Texas Back Institute as New CLARITY Trial Site - Ortho Spine News
Aclarion announces Texas Back Insitute as new CLARITY trial site - TipRanks
Aclarion Inc. Partners with Texas Back Institute for CLARITY Clinical Trial to Enhance Chronic Low Back Pain Treatment - Nasdaq
History Says Now Is the Time to Buy Nvidia Stock - The Globe and Mail
Aclarion Welcomes Advocate Health as CLARITY Trial Site - Ortho Spine News
Major Breakthrough: Advocate Health to Test AI-Powered Spine Pain Diagnostic in 300-Patient Trial - Stock Titan
Aclarion secures funding for pivotal CLARITY trial - MSN
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana - Ortho Spine News
Aclarion (ACON) Partners with Louisiana Spine Institute to Expan - GuruFocus
Aclarion announces agreement with the Spine Institute of Louisiana - TipRanks
Aclarion Expands Nociscan Access with Commercial Agreement at Spine Institute of Louisiana - Nasdaq
Revolutionary Spine Pain Technology Nociscan Achieves 97% Success Rate, Expands to 17 Medical Centers - Stock Titan
Aclarion stock hits 52-week low at $7.25 amid steep annual decline By Investing.com - Investing.com South Africa
Aclarion stock hits 52-week low at $7.25 amid steep annual decline - Investing.com
Aclarion, Inc. (NASDAQ:ACON) Short Interest Update - Defense World
Aclarion Inc Files For Mixed Shelf Of Up To $150 MlnSEC Filing - marketscreener.com
Aclarion Releases Updated Investor Presentation at Showcase - TipRanks
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025 - The Manila Times
Aclarion, Inc. to Present at Planet MicroCap Showcase: VEGAS 2025 on Chronic Low Back Pain Solutions - Nasdaq
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet ... - Bluefield Daily Telegraph
Aclarion's Revolutionary AI Approach to Chronic Back Pain: New Investor Strategy Revealed at MicroCap Vegas - Stock Titan
3 Reasons to Buy Amazon Stock Like There's No Tomorrow - The Globe and Mail
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis - Ortho Spine News
Aclarion's Nociscan Demonstrates Cost-Effectiveness and Improved Surgical Success Compared to Provocative Discography - Nasdaq
New Research: AI-Powered Spine Technology Cuts Patient Costs by $1,712, Boosts Surgery Success 10% - Stock Titan
NOCISCAN touted as lumbar pain diagnostic advance - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub - The Manila Times
Aclarion, Inc. SEC 10-K Report - TradingView
Aclarion stock hits 52-week low at $9.68 amid steep annual decline - Investing.com Canada
Aclarion stock hits 52-week low at $9.68 amid steep annual decline By Investing.com - Investing.com South Africa
Aclarion ‘s Nociscan now available in Santa Monica at MICSC - TipRanks
Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California - The Manila Times
Revolutionary AI-Powered Back Pain Diagnostic Tool Gains Ground in Los Angeles Healthcare Market - Stock Titan
EXCLUSIVE: March's 20 Most-Searched Tickers On Benzinga Pro — Where Do Tesla, Nvidia, Apple, Applovin Stock Rank?Apple (NASDAQ:AAPL), Aclarion (NASDAQ:ACON) - Benzinga
Aclarion, Inc. Delays Annual Report Filing - TipRanks
Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives - Ortho Spine News
Aclarion provides corporate update following Q1 strategic initiatives - TipRanks
Aclarion Inc Azioni (ACON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.51%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):